Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 190

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

Open access
Myers, Regina M., Li, Yimei, Barz Leahy, Allison, Barrett, David M., Teachey, David T., Callahan, Colleen, Fasano, Christina C., Rheingold, Susan R., DiNofia, Amanda, Wray, Lisa, Aplenc, Richard, Baniewicz, Diane, Liu, Hongyan, Shaw, Pamela A., Pequignot, Edward, Getz, Kelly D., Brogdon, Jennifer L., Fesnak, Andrew D., Siegel, Donald L., Davis, Megan M., Bartoszek, Chelsie, Lacey, Simon F., Hexner, Elizabeth O., Chew, Anne, Wertheim, Gerald B., Levine, Bruce L., June, Carl H., Grupp, Stephan A., Maude, Shannon L. · 2021 · Journal of Clinical Oncology

Abstract

PURPOSE: CD19-targeted chimeric antigen receptor (CAR)–modified T cells demonstrate unprecedented responses in B-cell acute lymphoblastic leukemia (B-ALL); however, relapse remains a substantial challenge. Short CAR T-cell persistence contributes to this risk; therefore, strategies to improve persistence are needed. METHODS: We conducted a pilot clinical trial of a humanized CD19 CAR T-cell product (huCART19) in children and young adults with relapsed or refractory B-ALL (n = 72) or B-lymphoblastic lymphoma (n = 2), treated in two cohorts: with (retreatment, n = 33) or without (CAR-naive, n = 41) prior CAR exposure. Patients were monitored for toxicity, response, and persistence of huCART19. RESULTS: Seventy-four patients 1-29 years of age received huCART19. Cytokine release syndrome developed in 62 (84%) patients and was grade 4 in five (6.8%). Neurologic toxicities were reported in 29 (39%), three (4%) grade 3 or 4, and fully resolved in all cases. The overall response rate at 1 month after infusion was 98% (100% in B-ALL) in the CAR-naive cohort and 64% in the retreatment cohort. At 6 months, the probability of losing huCART19 persistence was 27% (95% CI, 14 to 41) for CAR-naive and 48% (95% CI, 30 to 64) for retreatment patients, whereas the incidence of B-cell recovery was 15% (95% CI, 6 to 28) and 58% (95% CI, 33 to 77), respectively. Relapse-free survival at 12 and 24 months, respectively, was 84% (95% CI, 72 to 97) and 74% (95% CI, 60 to 90) in CAR-naive and 74% (95% CI, 56 to 97) and 58% (95% CI, 37 to 90) in retreatment cohorts. CONCLUSION: HuCART19 achieved durable remissions with long-term persistence in children and young adults with relapsed or refractory B-ALL, including after failure of prior CAR T-cell therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.20.03458

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 190

Metadata

Authors
Myers, R. M., Li, Y., Barz Leahy, A., Barrett, D. M., Teachey, D. T., Callahan, C., Fasano, C. C., Rheingold, S. R., DiNofia, A., Wray, L., Aplenc, R., Baniewicz, D., Liu, H., Shaw, P. A., Pequignot, E., Getz, K. D., Brogdon, J. L., Fesnak, A. D., Siegel, D. L., Davis, M. M., Bartoszek, C., Lacey, S. F., Hexner, E. O., Chew, A., Wertheim, G. B., Levine, B. L., June, C. H., Grupp, S. A., & Maude, S. L.
Venue
Journal of Clinical Oncology
Published
2021-09-20
Volume
39
Issue
27
Pages
3044-3055
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3173305141
Cited by
190
References
9
FWCI
10.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. https://app.cochat.ai/papers/10.1200/jco.20.03458
The paper
Myers, R. M., Li, Y., Barz Leahy, A., Barrett, D. M., Teachey, D. T., Callahan, C., Fasano, C. C., Rheingold, S. R., DiNofia, A., Wray, L., Aplenc, R., Baniewicz, D., Liu, H., Shaw, P. A., Pequignot, E., Getz, K. D., Brogdon, J. L., Fesnak, A. D., Siegel, D. L., . . . Maude, S. L. (2021). Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.03458

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.